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Toxicology of FK-506 in the Lewis Rat 
M.A. Nalesnik, S. TodD, N. Murase, S. Gryzan, P-H. Lee, L. Makowka, and T.E. Starzl 
FK-506 (FK), like all other known immu-nosuppressive agents, may be expected to 
demonstrate certain undesirable side effects, 
eg, infection, neoplasia. These effects must 
currently be accepted as common to the 
immunosuppressed state. The present study 
was undertaken to explore whether other toxic 
effects peculiar to FK exist. Because most of 
our initial transplantation studies were per-
formed in the rat, this animal was chosen as 
the first model for toxicological studies. 
MATERIALS AND METHODS 
Animals 
Male Lewis rats were obtained from Harlan Sprague 
Dawley Co, Indianapolis. The animals were housed in 
accordance with institutional guidelines and received food 
and water ad libitum. 
Drug 
FK was supplied in powder form by the Fujisawa 
Pharmaceutical Co, Ltd, Osaka, Japan. All concentra-
tions were made up in normal sterile saline and adminis-
tered to experimental animals per os by feeding syringe. 
Experimental Design 
One hundred-twenty five rats were divided into five 
groups of 25 animals each. Group 1 served as a control 
group and received placebo daily . Group 2 received FK 
~ at 0.5 mg/kg / d. Group 3 received 1.0 mg/kg/d, 
Group 4 received 2.0 mg/kg/d, and group 5 received 4.0 
mg/kg/d. Five randomly chosen animals from each group 
were killed on days 7,14,21,28, and 34. 
Baseline body weights were obtained, and the animals 
were weighed at three- to four-day intervals thereafter. 
At time of sacrifice, blood was collected for chemical and 
hematologic analysis. Preliminary analysis of some of 
these studies is available for the current communication. 
Autopsies were performed on all killed animals. The 
spleen, thymus, kidney, and liver were weighed and 
processed for light microscopy. Tissue was also stored for 
future electron microscopy. 
RESULTS 
Body Weight 
The mean body weight for each group is 
graphically demonstrated in Fig 1. It is appar-
ent that group 5 animals sustained a net 
weight loss at the outset of the experiment in 
contrast to all other groups. This process 
reached its nadir on day 13 when this group 
dropped to a mean 6% loss of original body 
weight. However, these animals recovered 
their original body weight by day 13 and 
continued to gain normally thereafter. At the 
conclusion of the experiment, the mean weight 
for the remaining animals in group 5 was 
350.6 g and that for control animals, 357.6 g. 
Gross and Histopathologic Studies 
No gross organ abnormalities were appar-
ent at autopsy. Thymus weights showed slight 
reductions, which appeared related to drug 
dosage (Fig 2) . No similar weight changes in 
the kidney or liver were apparent. Spleen 
weights will require further statistical analysis 
before offering preliminary comments. 
Histologically, the changes in the thymus 
were most striking (Fig 3). An increased 
corticomedullary ratio was observed that 
appeared proportional to drug dosage. This 
change was accompanied by increased phago-
cytic activity in the cortex. 
The pancreas demonstrated small numbers 
of isola ted acinar cells undergoing necrosis 
(Fig 4). In some cases, rare mitoses of acinar 
cells were also observed. 
With high doses of drug, a perivascular 
eosinophilia was observed to be localized in 
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Fig 1 . Effect of FK on rat 
body weight . Group 1 (.) ; p la-
cebo; group 2 (0); 0 .5 mg / kg / 
d; group 3 (.) ; 1.0 mg / kg / d; 
group 4 (0 ); 2.0 mg / kg / d; 
group 5 ( .... ); 4 .0 mg / kg/d. 
Weights are represented as 
means. Number of animals per 
group : days O. 3 . 7 . n - 25; days 
10 . 13. n 20; days 17. 20 . n 
15 ; day s 24 . 27. n - 10; days 
3 1.34. n - 5 . Day of Sac rif ic 
most cases to vessel s in the lung ( Fig 5) . C lose 
histological exam inat ion failed to revea l any 
ev idence of vascular damage in association 
with this fin ding 
Sections orskin, mu. cIe, rat, intestine, liver, 
kidney, spleen, and heart were al 0 examined . 
o reproducible changes were seen in these 
organs at the drug dosages administered. 
Blood Studies 
These studies will be presented more fully 
in a subsequent publication (in prepara tion) . 
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Fig 2. Effect of FK on thymus weight at day 34. 
Each bar represents the mean and SE of five animals per 
group killed on the last day of the experiment (day 34). 
Groups are as in Fig 1. 
Fig 3 . Thymus from FK-treated animal on day 7 
shows a reduction of the medullary regions. This loss 
was progressive over time (H&E : original magnification 
x 32). 
FK TOXICOLOGY 
Fig 4 . Pancreas from FK- t reat ed animal showing 
small focus of necrotic acinar cells (H&E; original magni-
fication x 325). 
An early observation of interest is the trend 
for increased blood glucose levels in treated 
groups. As shown in Fig 6, this trend appears 
to be exaggerated with time in the animals. 
Statistical analysis of this data is currently 
underway . 
DISCUSSION 
FK has been shown to be a potent immuno-
suppressive agent by Ochiai et al.I Confirming 
studies at our institution 2•3 have indicated that 
the drug does indeed possess important in vivo 
antirejection effects . The current study 
explores some of the possible toxicological 
effecis of this compound in the Lewis ra t. 
No spontaneous deaths occurred over the 
interval of the study. High-dose rats experi-
enced an initial loss of body weight. However, 
they almost fully recovered from this loss over 
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Fig 5. Lung from FK-treated rat showing perivascu-
lar eosinophilic infiltration. No direct vessel damage can 
be appreciated in this section. (H&E; original mangifica-
tion x325). 
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Fig 6 . Effect of FK on blood glucose levels. Means 
and SE of blood glucose values were measured on days 
7 and 34. Groups are as in Fig 1 . Number of animals per 
group: day 7, 5; day 34, 5. 0, Group 1; e, group 3; •. 
group 4; O. group 5. 
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the next 2 weeks. A dose-dependent reduction 
of thymus weight indicated that the drug was 
exerting an influence on the immune system 
at doses administered. The histological 
changes in this organ resembled those 
described for cyclosporine A (CsA): which 
reflects a form of medullary atrophy. 
A possible low-grade effect on the pancreas 
was manifested by histological changes corre-
sponding to an increased pancrea tic acinar 
cell turnover. Pancreatic islets were not spe-
cifically evaluated because they are best 
examined by other means. However, a trend 
for treated rats to demonstrate higher levels of 
blood glucose was noted in this study. This 
finding must be interpreted with caution 
because specimens were not obtained in a 
fasting state and may thus be artifactual. 
Nevertheless, it targets this area as worthy of 
further study, especially in light of the known 
effects of CsA on the pancreatic islets .s 
No clinicopathologic evidence of vasculitis 
was seen in the present study. This finding is 
in contrast to results in canine models in 
which vascular toxicity represents a real and 
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possibly rate-limiting factor in the use of the 
drug (Thiru, personal communication; Deme-
tris, unpublished observations). 
Some rat histological slides were kindly 
made available for our review by the Fujisawa 
Co. In their animals, which received doses up 
to eight times that administered in our study, 
additional toxic manifestations were obvious 
in renal tubules and hepatocytes . 
In summary, FK is a new compound with 
clinically exploitable major activity involving 
the immune system. It is not without effects in 
other organ systems, however. The relative 
importance and species specificity of these 
effects are currently being explored. The most 
important of these toxic effects involves vascu-
lar damage as seen in the dog . Similar damage 
has not as yet been documented in the rat. 
More extensive studies, especially in subhu-
man primates, will be required to resolve these 
issues. At present, FK appears to hold consid-
erable promise as an important member in the 
polypharmaceutical approach to antirejection 
therapy. 
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